Key Highlights

  • Cadrenal Therapeutics received a reiterated Buy rating and $13 price target from H.C. Wainwright.
  • The rating follows a Type D meeting where the FDA aligned on the CAD-1005 Phase 3 primary endpoint and trial design.
  • The trial targets heparin-induced thrombocytopenia (HIT).
  • Initiation of the study is contingent upon securing additional funding or a strategic partnership.

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) received a reiterated Buy rating and $13 price target from H.C. Wainwright following a Type D meeting where the FDA aligned on the CAD-1005 Phase 3 primary endpoint and placebo-controlled trial design for heparin-induced thrombocytopenia.

What Happened

The regulatory agreement provides a clear registrational pathway, though the initiation of the study is currently contingent upon securing additional funding or a strategic partnership.

Market Reaction

The disclosed information does not include stock price or trading data for Cadrenal Therapeutics following the reiterated rating.

Outlook

Securing additional funding or a strategic Partnership represents the key near-term step before Cadrenal Therapeutics can initiate its Phase 3 trial for CAD-1005 in HIT.